Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant NA17-A and Peptide Vaccine in Ocular Melanoma
NCT00036816Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2002
- Primary completion
- Feb 2003
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of NA-17.A2, mart-1 antigen, gp100 antigen, tyrosinase peptide in Ocular melanoma (OM), sponsored by European Organisation for Research and Treatment of Cancer. Started Feb 2002; status: terminated.
02
Drugs
NA-17.A2mart-1 antigengp100 antigentyrosinase peptide
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT00036816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036816.